Drugs / Anaferon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03162458 | Jan → Apr 2015 | respiratory tract infectious disorder | Materia Medica Holding | Completed | Met primary |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT03707912 | Oct 2018 → Mar 2019 | viral respiratory tract infection | Materia Medica Holding | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anaferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03162458 ↗ |
| Route | Oral | “Oral administration.” NCT03707912 ↗ |